18 research outputs found
De alveitares a veterinários: notas históricas sobre a medicina animal e a Escola Superior de Medicina Veterinária São Bento de Olinda, Pernambuco (1912-1926)
Preclinical evaluation in rodents of the pharmacokinetic profile of benzaldehyde semicarbazone free and complexed with ß-cyclodextrin
Objetivos: Avaliar a farmacocinética e a distribuição tecidual do benzaldeído semicarbazona livre (BS) e incluso em ß-Ciclodextrinas (BS/ß-CD) após administração de diversas doses por diferentes vias de administração. Metodologia: As concentrações plasmáticas de BS foram quantificadas através de método analítico por CLAE-UV desenvolvido e validado, após administração das doses de 10 mg/kg i.v. bolus e 50 e 100 mg/kg p.o. da droga livre e 10 mg/kg i.v. bolus e 50 mg/kg p.o. da droga complexada a ratos Wistar (n = 8 animais/grupo). Os perfis plasmáticos foram avaliados individualmente pelas abordagens não-compartimental e compartimental para determinação dos parâmetros farmacocinéticos. A avaliação compartimental foi realizada utilizando software Scientist 2.0.1 (Micromath®). A ligação do BS a proteínas plasmáticas foi determinada por ultrafiltração na faixa de 1,0 a 60,0 µg/mL. O perfil de penetração tecidual da droga livre e complexada foi investigado em diferentes órgãos utilizando o método de homogeneizado de tecido até 5 h após administração de dose 10 mg/kg i.v. A penetração cerebral também foi avaliada para a droga livre e inclusa em ß-CD após a dose de 50 mg/kg até 4 h após administração (n = 3 animais/tempo coleta). Resultados e Discussão: A fração livre do BS em plasma de ratos foi de 34 ± 5%. O modelo de um compartimento descreveu adequadamente todos os perfis plasmáticos estudados. Após doses intravenosa (10 mg/kg) e oral (50 mg/kg), parâmetros farmacocinéticos como Vd (1,6 ± 0,5 e 2,2 ± 0,8 L/kg, respectivamente) e Cltot (1,4 ± 0,5 and 1,8 ± 0,5 L/h×kg, respectivamente) foram maiores para o BS complexado em relação à droga livre, embora os t1/2 (0,8 ± 0,1 h-1) mantiveram-se similares (p < 0,05). A biodisponibilidade oral do BS/ß-CD (~37%) foi aproximadamente o dobro daquela observada para a droga livre (~20%). O fator de penetração cerebral após doses intravenosa (2,8) e oral (2,5), assim como tempo de residência médio, foram maiores para a droga complexada, independente da via de administração avaliada. Conclusões: A farmacocinética do BS livre e complexado mostra uma rápida distribuição tecidual e uma rápida eliminação. A maior penetração cerebral do complexo em relação à droga livre mostra que a ß-CD é uma estrutura capaz de vetorizar, reter e modificar a liberação do BS nesse órgão, explicando os achados farmacodinâmicos prévios.Purpose: This study aimed to investigate the pharmacokinetics and tissue distribution of benzaldehyde semicarbazone (BS) free and complexed with ß- cyclodextrin (BS/ß-CD) after administration to rodents at different doses by diverse routes. Methodology: BS plasma concentrations were determinated in Wistar rats after administration of 10 mg/kg i.v bolus and 50 and 100 mg/kg p.o. for the free drug and 10 mg/kg i.v. bolus and 50 mg/kg for the BS/ß-CD (n = 8/group), using a HPLCUV method specifically developed and validated. Individual plasma profiles obtained were evaluated by non-compartmental and compartmental approaches, using the software Scientist 2.0.1 (MicroMath®), analysis to determine the pharmacokinetic parameters. BS protein binding was determined by ultrafiltration at a concentration range of 1.0 a 60.0 µg/mL. BS tissue penetration after free or ß-CD-complexed drug administration was investigated in different tissues homogenates up to 5 h after i.v. bolus dosing of 10 mg/kg dose. Brain penetration of the free and complexed drug was also evaluated up to 4 h after administration of 50 mg/kg p.o. dose (3 animals/time point). Results and Discussion: BS free fraction in plasma was 34 ± 5%. The one-compartmental model described adequately the plasma profiles of all groups investigated. After i.v. (10 mg/kg) and p.o. (50 mg/kg) doses, pharmacokinetic parameters such as Vd (1.6 ± 0.5 e 2.2 ± 0.8 L/kg, respectively) and CLtot (1.4 ± 0.5 and 1.8 ± 0.5 L/h×kg, respectively) were higher for the BS/ß-CD than for the free drug, although the t1/2 (0.8 ± 0.1 h-1) remained the same (p < 0.05). The oral bioavailability of the BS/ß-CD (~ 37%) was approximately 2-fold of that observed for the free BS (~ 20%). The brain penetration factor after i.v. (2.8) and p.o. (2.5) doses, as well as the mean residence time, were higher after BS/ß-CD dosing than after free drug dosing, regardless of the route administrated. Conclusions: BS pharmacokinetics (free and complexed) showed a fast tissue distribution and elimination. The higher brain penetration of the drug after the administration of the complex reveals that the ß-CD may be a potential system to carrier, retain and change the delivery of BS in this organ, explaining the previous pharmacodynamic results
Preclinical evaluation in rodents of the pharmacokinetic profile of benzaldehyde semicarbazone free and complexed with ß-cyclodextrin
Objetivos: Avaliar a farmacocinética e a distribuição tecidual do benzaldeído semicarbazona livre (BS) e incluso em ß-Ciclodextrinas (BS/ß-CD) após administração de diversas doses por diferentes vias de administração. Metodologia: As concentrações plasmáticas de BS foram quantificadas através de método analítico por CLAE-UV desenvolvido e validado, após administração das doses de 10 mg/kg i.v. bolus e 50 e 100 mg/kg p.o. da droga livre e 10 mg/kg i.v. bolus e 50 mg/kg p.o. da droga complexada a ratos Wistar (n = 8 animais/grupo). Os perfis plasmáticos foram avaliados individualmente pelas abordagens não-compartimental e compartimental para determinação dos parâmetros farmacocinéticos. A avaliação compartimental foi realizada utilizando software Scientist 2.0.1 (Micromath®). A ligação do BS a proteínas plasmáticas foi determinada por ultrafiltração na faixa de 1,0 a 60,0 µg/mL. O perfil de penetração tecidual da droga livre e complexada foi investigado em diferentes órgãos utilizando o método de homogeneizado de tecido até 5 h após administração de dose 10 mg/kg i.v. A penetração cerebral também foi avaliada para a droga livre e inclusa em ß-CD após a dose de 50 mg/kg até 4 h após administração (n = 3 animais/tempo coleta). Resultados e Discussão: A fração livre do BS em plasma de ratos foi de 34 ± 5%. O modelo de um compartimento descreveu adequadamente todos os perfis plasmáticos estudados. Após doses intravenosa (10 mg/kg) e oral (50 mg/kg), parâmetros farmacocinéticos como Vd (1,6 ± 0,5 e 2,2 ± 0,8 L/kg, respectivamente) e Cltot (1,4 ± 0,5 and 1,8 ± 0,5 L/h×kg, respectivamente) foram maiores para o BS complexado em relação à droga livre, embora os t1/2 (0,8 ± 0,1 h-1) mantiveram-se similares (p < 0,05). A biodisponibilidade oral do BS/ß-CD (~37%) foi aproximadamente o dobro daquela observada para a droga livre (~20%). O fator de penetração cerebral após doses intravenosa (2,8) e oral (2,5), assim como tempo de residência médio, foram maiores para a droga complexada, independente da via de administração avaliada. Conclusões: A farmacocinética do BS livre e complexado mostra uma rápida distribuição tecidual e uma rápida eliminação. A maior penetração cerebral do complexo em relação à droga livre mostra que a ß-CD é uma estrutura capaz de vetorizar, reter e modificar a liberação do BS nesse órgão, explicando os achados farmacodinâmicos prévios.Purpose: This study aimed to investigate the pharmacokinetics and tissue distribution of benzaldehyde semicarbazone (BS) free and complexed with ß- cyclodextrin (BS/ß-CD) after administration to rodents at different doses by diverse routes. Methodology: BS plasma concentrations were determinated in Wistar rats after administration of 10 mg/kg i.v bolus and 50 and 100 mg/kg p.o. for the free drug and 10 mg/kg i.v. bolus and 50 mg/kg for the BS/ß-CD (n = 8/group), using a HPLCUV method specifically developed and validated. Individual plasma profiles obtained were evaluated by non-compartmental and compartmental approaches, using the software Scientist 2.0.1 (MicroMath®), analysis to determine the pharmacokinetic parameters. BS protein binding was determined by ultrafiltration at a concentration range of 1.0 a 60.0 µg/mL. BS tissue penetration after free or ß-CD-complexed drug administration was investigated in different tissues homogenates up to 5 h after i.v. bolus dosing of 10 mg/kg dose. Brain penetration of the free and complexed drug was also evaluated up to 4 h after administration of 50 mg/kg p.o. dose (3 animals/time point). Results and Discussion: BS free fraction in plasma was 34 ± 5%. The one-compartmental model described adequately the plasma profiles of all groups investigated. After i.v. (10 mg/kg) and p.o. (50 mg/kg) doses, pharmacokinetic parameters such as Vd (1.6 ± 0.5 e 2.2 ± 0.8 L/kg, respectively) and CLtot (1.4 ± 0.5 and 1.8 ± 0.5 L/h×kg, respectively) were higher for the BS/ß-CD than for the free drug, although the t1/2 (0.8 ± 0.1 h-1) remained the same (p < 0.05). The oral bioavailability of the BS/ß-CD (~ 37%) was approximately 2-fold of that observed for the free BS (~ 20%). The brain penetration factor after i.v. (2.8) and p.o. (2.5) doses, as well as the mean residence time, were higher after BS/ß-CD dosing than after free drug dosing, regardless of the route administrated. Conclusions: BS pharmacokinetics (free and complexed) showed a fast tissue distribution and elimination. The higher brain penetration of the drug after the administration of the complex reveals that the ß-CD may be a potential system to carrier, retain and change the delivery of BS in this organ, explaining the previous pharmacodynamic results
The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids
Capsaicin, a topical analgesic used in the treatment of chronic pain, has irritant properties that frequently interrupt its use. In this work, the effect of nanoencapsulation of the main capsaicinoids (capsaicin and dihydrocapsaicin) on skin irritation was tested in humans. Skin tolerance of a novel vehicle composed of chitosan hydrogel containing nonloaded nanocapsules (CH-NC) was also evaluated. The chitosan hydrogel containing nanoencapsulated capsaicinoids (CH-NC-CP) did not cause skin irritation, as measured by an erythema probe and on a visual scale, while a formulation containing free capsaicinoids (chitosan gel with hydroalcoholic solution [CH-ET-CP]) and a commercially available capsaicinoids formulation caused skin irritation. Thirty-one percent of volunteers reported slight irritation one hour after application of CH-NC-CP, while moderate (46% [CH-ET-CP] and 23% [commercial product]) and severe (8% [CH-ET-CP] and 69% [commercial product]) irritation were described for the formulations containing free capsaicinoids. When CH-NC was applied to the skin, erythema was not observed and only 8% of volunteers felt slight irritation, which demonstrates the utility of the novel vehicle. A complementary in vitro skin permeation study showed that permeation of capsaicinoids through an epidermal human membrane was reduced but not prevented by nanoencapsulation
The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids
Capsaicin, a topical analgesic used in the treatment of chronic pain, has irritant properties that frequently interrupt its use. In this work, the effect of nanoencapsulation of the main capsaicinoids (capsaicin and dihydrocapsaicin) on skin irritation was tested in humans. Skin tolerance of a novel vehicle composed of chitosan hydrogel containing nonloaded nanocapsules (CH-NC) was also evaluated. The chitosan hydrogel containing nanoencapsulated capsaicinoids (CH-NC-CP) did not cause skin irritation, as measured by an erythema probe and on a visual scale, while a formulation containing free capsaicinoids (chitosan gel with hydroalcoholic solution [CH-ET-CP]) and a commercially available capsaicinoids formulation caused skin irritation. Thirty-one percent of volunteers reported slight irritation one hour after application of CH-NC-CP, while moderate (46% [CH-ET-CP] and 23% [commercial product]) and severe (8% [CH-ET-CP] and 69% [commercial product]) irritation were described for the formulations containing free capsaicinoids. When CH-NC was applied to the skin, erythema was not observed and only 8% of volunteers felt slight irritation, which demonstrates the utility of the novel vehicle. A complementary in vitro skin permeation study showed that permeation of capsaicinoids through an epidermal human membrane was reduced but not prevented by nanoencapsulation
Diminuição de ácidos graxos poliinsaturados e aumento de ácidos graxos saturados em lipídeos totais em pacientes com diabete melito tipo 2 (DM2) e microalbuminúria
40
Diminuição de ácidos graxos poliinsaturados e aumento de ácidos graxos saturados em lipídeos totais em pacientes com diabete melito tipo 2 (DM2) e microalbuminúria
40